Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBIT (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of EBIT data on record, last reported at -$24.0 million in Q4 2024.

  • For Q4 2024, EBIT rose 5.71% year-over-year to -$24.0 million; the TTM value through Dec 2024 reached -$102.7 million, up 4.84%, while the annual FY2024 figure was -$102.7 million, 4.84% up from the prior year.
  • EBIT reached -$24.0 million in Q4 2024 per FHTX's latest filing, down from -$23.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$13.7 million in Q1 2020 and bottomed at -$33.3 million in Q1 2023.
  • Average EBIT over 5 years is -$24.8 million, with a median of -$25.9 million recorded in 2021.
  • Peak YoY movement for EBIT: plummeted 68.54% in 2021, then surged 39.56% in 2023.
  • A 5-year view of EBIT shows it stood at -$20.8 million in 2020, then tumbled by 35.15% to -$28.1 million in 2021, then fell by 13.55% to -$31.9 million in 2022, then rose by 20.16% to -$25.5 million in 2023, then rose by 5.71% to -$24.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for EBIT were -$24.0 million in Q4 2024, -$23.9 million in Q3 2024, and -$26.6 million in Q2 2024.